Gene-Disorder Association · Article
Gene
SLC6A4 Solute Carrier Family 6 Member 4
×
First reported
1996
Supporting publications
26
Manually curated Approved treatment annotated
Association Review
In brief The association between SLC6A4 (Solute Carrier Family 6 Member 4) and Obsessive-Compulsive Disorder is well established and manually curated, with its 4 contributing sources — 2 of them expert-curated — recording a known molecular basis and a susceptibility locus.
Sources
4
Clinical variants
3
Symptoms
13
Compounds
7
Trials
39 of 1,305 via SLC6A4 compounds
Publications
26
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access 02
Provenance
Evidence and sources 4 sources
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access 2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access 04
Obsessive-Compulsive Disorder
The disorder 11 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access 05
Phenotype
Clinical features 5 clinical features
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access 06
ClinVar and variant evidence
Genetic basis 3 clinical variants
ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.
Request access 07
Genomic context
Regulatory context 1 regulatory element
GeneHancer regulatory elements for the pair, with coordinates, score, element type and supporting literature.
Request access 08
Mechanism overlap
Shared mechanisms Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.
Request access 09
Interventions
Therapeutics 7 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access 10
Human studies
Clinical trials 1,305 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access 26 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access 12
Provenance
References & sources 23 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access 
